SureTrader SPDR Advertisement SPDR Advertisement
Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator stervc, HDOGTX, sunspotter, Nadia, NUMBER7, RastaOzMonstah
Search This Board:
Last Post: 2/26/2015 10:52:13 PM - Followers: 174 - Board type: Free - Posts Today: 241

RCHA Patent for Treatment of Hodgkin’s Lymphoma
Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma, utility patent application number 61998397, entitled COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS FOR THE TREATMENT OF HODGKIN’S LYMPHOMA.
RCHA Recent News
Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014.  In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases.  Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life.  Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities.  Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:


Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells (WBC) in patients depleted of these elements due to various conditions. 

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs, and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000. Based on this incidence,the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares


Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003



Daily View
Weekly View
3 Month Daily View
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RCHA News: Amended Quarterly Report (10-q/a) 02/25/2015 03:01:47 PM
RCHA News: Current Report Filing (8-k) 02/24/2015 05:13:25 PM
RCHA News: Quarterly Report (10-q) 02/23/2015 02:30:28 PM
RCHA News: Statement of Ownership (sc 13g) 02/23/2015 11:28:18 AM
RCHA News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 02/17/2015 02:22:03 PM
#3430  Sticky Note DRUG TRIALS START AROUND FEB. 15TH HUGE NEWS IMMINENT! vegasvic 02/11/15 11:12:06 AM
#2921  Sticky Note RCHA Expects FDA Orphan Drug Fast Track Approval… stervc 02/07/15 10:05:01 AM
#1165  Sticky Note RCHA 02/04/2015 Rich Pharmaceuticals Announces Completion of the HDOGTX 02/05/15 12:12:57 AM
#5341 Homebrew 02/26/15 10:52:13 PM
#5340   Doubt it. Pinks and most real OTCBB do Axeman 02/26/15 09:33:20 PM
#5339   Going up .0019 range tomorrow nice After hour durrdurr 02/26/15 07:56:50 PM
#5338   Don't say I didn't warn you, typical pump agribusiness72 02/26/15 07:46:15 PM
#5337   Dont forget NTEK! What happened to the photos Sleepy2016 02/26/15 07:16:19 PM
#5336   After news comes out ace1mc 02/26/15 06:55:42 PM
#5335   If anyone wants to get a Feel so OTCdoc 02/26/15 06:26:16 PM
#5334   I can relate to that i.e. BGMD and OTCdoc 02/26/15 06:23:32 PM
#5332   It could very well be a scam,,,,,theres stuff OTCdoc 02/26/15 06:17:39 PM
#5331   Agreed. $RCHA is not even regular OTC Pink. PetePham 02/26/15 06:11:12 PM
#5330   Your use of the term "scam" when referring Reptos 02/26/15 05:39:55 PM
#5329   2/4 O/S was 731 mil, now 1,122,753,911 pathetic power_forward 02/26/15 05:37:35 PM
#5328   Current O/S: 1,122,753,911 as of yesterday power_forward 02/26/15 05:35:48 PM
#5327   Filings are OUTDATED, only the TA is TRUTHFUL--sorry power_forward 02/26/15 05:32:30 PM
#5326   email sent to TA--Dilution is Appalling here power_forward 02/26/15 05:31:22 PM
#5325   Not according to the most recent filing. Like Reptos 02/26/15 05:29:34 PM
#5324   "Rich Pharmaceuticals Inc(OTCBB:RCHA) is a leading biopharmaceuticals firm" sunspotter 02/26/15 05:26:50 PM
#5323   too much dilution power_forward 02/26/15 05:25:44 PM
#5322   no, O/S is 1.22 BILLION, probably higher after today power_forward 02/26/15 05:23:08 PM
#5321   IHub actually shows it at .00154 ( Reptos 02/26/15 05:21:11 PM
#5320   Rich Pharmaceuticals Inc(OTCBB:RCHA) Updates On RP-323 Study Drug stressfreeliving 02/26/15 05:16:46 PM
#5319   Nice 19.9M+ Buy Trade. stressfreeliving 02/26/15 05:09:47 PM
#5318   Tomorrow is Friday. Don't forget. LOL Reptos 02/26/15 04:41:20 PM
#5317   There was one Form T trade posted Reptos 02/26/15 04:39:56 PM
#5316   Trading Breakdown for TODAY stressfreeliving 02/26/15 04:35:48 PM
#5315   Tomarrows a friday dont forget. OTCdoc 02/26/15 04:34:10 PM
#5314   I didn't track it down but let me PetePham 02/26/15 04:27:03 PM
#5313   do you have last 10 trades for rcha mick 02/26/15 04:25:12 PM
#5312   Wow...that's what I said the 20M AON at PetePham 02/26/15 04:25:06 PM
#5311   Buys exceeded sells by about 25% today. That Reptos 02/26/15 04:25:00 PM
#5310   RCHA .0015 19,919,399 16:08:57 24seven 02/26/15 04:12:50 PM
#5309   Without more volume ,MM's find it easy to Reptos 02/26/15 04:10:35 PM
#5308   We will be setting up for a big PetePham 02/26/15 04:08:44 PM
#5307   Shaky hand sell their shares. We will form PetePham 02/26/15 04:08:01 PM
#5306   Predictions for next week? Will there be news? Imarket13 02/26/15 03:56:07 PM
#5305   can rcha close at 0.0017 at closing? mick 02/26/15 03:51:31 PM
#5304   Shares Out.859.8M/ AT AMERITRADE THE OUTSTANDING SHARES ARE mick 02/26/15 03:46:20 PM
#5303   is that before or after your prediction laureus69 02/26/15 03:45:47 PM
#5302   I am holding my shares till next wed ace1mc 02/26/15 03:35:21 PM
#5301   RCHA: No problem :-) $$$ RCHA $$$ Papa Bear 02/26/15 02:57:03 PM
#5300   THANX. tiller 02/26/15 02:54:55 PM
#5299   Good thing or bad thing??? jonestint 02/26/15 02:53:43 PM
#5298   ask thinning out. shares being accumulated by deep pockets! Jsmooth37 02/26/15 02:47:44 PM
#5297   shook some foos! thanks again 14s are golden. Jsmooth37 02/26/15 02:46:32 PM
#5296   you need to change your trading acct. kragdason 02/26/15 02:45:26 PM
#5295 Papa Bear 02/26/15 02:44:04 PM
#5294   Please post link from where your info. came. tiller 02/26/15 02:41:16 PM
#5293   Seems that way...looks like 0012s and 001s wont OTCdoc 02/26/15 02:38:43 PM
#5292   I gobbled them up! Jsmooth37 02/26/15 02:38:14 PM
#5291   almost bye bye to the 14's. GoHighOrGoHigh 02/26/15 02:34:40 PM